Pentraxin 3 Inhibits Complement-driven Macrophage Activation to Restrain Granuloma Formation in Sarcoidosis

Data de publicação:

Autores da FMUP

  • Hélder Novais E Bastos

    Autor

  • Oksana Sokhatska

    Autor

  • José Luís Dias Delgado

    Autor

  • Antonio Manuel Martins De Morais

    Autor

Participantes de fora da FMUP

  • Gonçales, RA
  • Duarte-Oliveira, C
  • Antunes, D
  • Jacob, M
  • Rolo, R
  • Campos, CF
  • Sasaki, SD
  • Donato, A
  • Mapelli, SN
  • Costa, S
  • Moura, CS
  • Torrado, E
  • van de Veerdonk, FL
  • Weichhart, T
  • Lambris, JD
  • Silvestre, R
  • Garlanda, C
  • Mantovani, A
  • Cunha, C
  • Carvalho, A

Unidades de investigação

Abstract

Rationale: Sarcoidosis is a multisystemic inflammatory disease characterized by the formation of granulomas in response to persistent stimuli. The long pentraxin PTX3 (pentraxin 3) has emerged as a component of humoral innate immunity with essential functions in the resolution of inflammation, but its role during granuloma formation is unknown. Objectives: To evaluate PTX3 as a modulator of pathogenic signals involved in granuloma formation and inflammation in sarcoidosis. Methods: Peripheral blood mononuclear cells obtained from patients with sarcoidosis harboring loss-of-function genetic variants and gene-deleted mice were used to assess the role of PTX3 in experimental models of granuloma formation in vitro and in vivo. The identified mechanisms of granulomatous inflammation were further evaluated in tissue and BAL samples and correlated with the disease course. Measurements and Main Results: We have identified a molecular link between PTX3 deficiency and the pathogenic amplification of complement activation to promote granuloma formation. Mechanistically, PTX3 deficiency licensed the complement component C5a-mediated activation of the metabolic checkpoint kinase mTORC1 (mammalian target of rapamycin complex 1) and the reprogramming of macrophages toward increased glycolysis to foster their proliferation and aggregation. This process sustained the further recruitment of granulomapromoting immune cells and the associated proinflammatory microenvironment and influenced the clinical course of the disease. Conclusions: Our results identify PTX3 as a pivotal molecule that regulates complement-mediated signaling cues in macrophages to restrain granulomatous inflammation and highlight the therapeutic potential of this signaling axis in targeting granuloma formation in sarcoidosis.

Dados da publicação

ISSN/ISSNe:
1073-449X, 1535-4970

American Journal of Respiratory and Critical Care Medicine  American Thoracic Society

Tipo:
Article
Páginas:
1140-1152
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 4

Citações Recebidas na Scopus: 14

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • sarcoidosis; humoral immunity; granuloma; macrophages; complement system proteins

Financiamento

Proyectos asociados

Fibrosing ILD Biomarkers That Rule Acceleration (FIBRALUNG) -NCT05635032

Investigador Principal: Hélder Novais e Bastos

Estudo Observacional Académico (FIBRALUNG) . FCT . 2021

Chronic Bronchopulmonary aspergillosis patients with underlying chronic obstructive pulmonary disease: providing grounds for biomarkers search through clinical phenotyping

Investigador Principal: Hélder Novais e Bastos

Estudo Clínico Académico . 2020

Impact of Chronic Obstructive Pulmonary Disease in surgical outcomes of lung cancer patients undergoing curative intent surgery

Investigador Principal: Hélder Novais e Bastos

Estudo Clínico Académico . 2021

Pulmonary Emphysema Regional Distribution and Extent from Chest Computed Tomography is Associated with Pulmonary Function Impairment in COPD Patients.

Investigador Principal: Hélder Novais e Bastos

Estudo Clínico Académico . 2021

Non-invasive assessment of Benign Tracheal Stenosis.

Investigador Principal: Hélder Novais e Bastos

Estudo Clínico Académico . 2020

Predictors of lung entrapment in malignant pleural effusion

Investigador Principal: Hélder Novais e Bastos

Estudo Clínico Académico . 2022

Citar a publicação

Partilhar a publicação